P
Profusa, Inc.
PFSACIK 0001859807NasdaqEmerging GrowthSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-35.80M
Total Assets
$3.77M
Equity
$-26.66M
Shares Out
4.66M
Op. Cash Flow
$-16.25M
Business
Profusa is a digital health technology company developing the Lumee biosensor platform, a subcutaneously injected passive sensor that measures real-time biochemistry including tissue oxygen and glucose levels. The company offers two lead product candidates: Lumee Oxygen, which received CE approval in Europe for wound care management in critical limb ischemia patients, and Lumee Glucose, a continuous glucose monitoring system currently in clinical development. Profusa operates across European and U.S. markets with a regulatory approval and commercial partnership strategy.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Government grant revenue | — | 100,000 | — | — | |
| Research and development | 3 | 2 | — | — | |
| General and administrative | 25 | 3 | — | — | |
| Total operating expenses | 28 | 5 | — | — | |
| Loss from operations | −28 | −5 | −2 | −1 | |
| Loss on change in the fair value of convertible notes | −3 | −311,000 | — | — | |
| Gain on the change in fair value of warrant liabilities | 895,000 | — | 701,148 | 6 | |
| Loss on the change in fair value of digital assets | −555,000 | — | — | — | |
| Interest expense (including related parties amounts of $1,330 and $2,400 for the years ended December 31, 2025 and 2024, respectively) | −3 | −4 | — | — | |
| Financing costs | −3 | — | — | — | |
| Other income | 16,000 | 5,000 | — | — | |
| Total other expense, net | −8 | −5 | 3 | 9 | |
| Net loss | −36 | −9 | 1 | 7 | |
| Net loss per share, basic (in Dollars per share) | −107.01 | −357.14 | 0.12 | 0.3 | |
| Net loss per share, diluted (in Dollars per share) | −107.01 | −357.14 | 0.12 | 0.3 | |
| Weighted-average common shares outstanding, basic (in Shares) | 334,762 | 25,844 | 5 | 5 | |
| Weighted-average common shares outstanding, diluted (in Shares) | 334,762 | 25,844 | 5 | 5 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 2 | 191,000 | 4,519 | 193,486 | — | |
| Prepaid expenses and other current assets | 541,000 | 69,000 | 6,750 | 318,218 | 332,396 | |
| Digital assets | 1 | — | — | — | — | |
| Total current assets | 4 | 260,000 | 2 | 511,704 | 1 | |
| Deferred offering costs | — | 3 | 2 | — | — | |
| Property and equipment, net | 8,000 | — | — | — | — | |
| Other non-current assets | 3,000 | 56,000 | — | — | — | |
| Total assets | 4 | 3 | 11 | 195 | 193 | |
| Accounts payable | 7 | 5 | — | — | — | |
| Excise tax payable | 2 | — | 2 | — | — | |
| Accrued expenses and other current liabilities | 6 | 4 | 449,114 | 448,480 | — | |
| Convertible notes payable (including notes payable to related parties of $4,160 and $25,056 as of December 31, 2025 and 2024, respectively) | 4 | 46 | — | — | — | |
| Promissory notes and other (including notes payable to related parties of $400 and $850 as of December 31, 2025 and 2024, respectively) | 1 | 910,000 | — | — | — | |
| PPP loan | 1 | 1 | — | — | — | |
| Total current liabilities | 22 | 57 | 5 | 935,751 | 106,511 | |
| Warrant liabilities at fair value | 298,000 | — | 156,639 | 857,787 | — | |
| Loans payable at fair value | 8 | — | — | — | — | |
| Total liabilities | 30 | 57 | 5 | 2 | 7 | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Total convertible preferred stock | — | 65 | — | — | — | |
| Common stock: $0.0001 par value 600,000,000 authorized shares at December 31, 2025 and 2024, and 1,232,052 and 25,844 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — | 519 | 519 | 519 | |
| Additional paid-in capital | 134 | 6 | — | — | — | |
| Accumulated deficit | −161 | −125 | −3 | −619,995 | −6 | |
| Total stockholders deficit | −27 | −119 | −110 | −619,476 | −6 | |
| Total liabilities and stockholders deficit | 4 | 3 | 11 | 195 | 193 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Noncash interest expense | 3 | 4 | — | — | |
| Noncash loss on change in fair value of convertible notes | 3 | 311,000 | — | — | |
| Noncash issuance of inducement shares and in connection with the merger | 7 | — | — | — | |
| Noncash issuance of warrants to financial advisor | 330,000 | — | — | — | |
| Noncash issuance of warrants associated for ELOC Warrants | 982,000 | — | — | — | |
| Loss on disposition of property and equipment, net | — | 2,000 | — | — | |
| Stock-based compensation expenses | 891,000 | 21,000 | — | — | |
| Noncash merger transaction costs | 500,000 | — | — | — | |
| Other receivables | — | 45,000 | — | — | |
| Prepaid expenses and other current assets | 211,000 | 77,000 | 311,468 | 322,396 | |
| Other non-current assets | 53,000 | −25,000 | — | — | |
| Accounts payable | 4 | 645,000 | — | — | |
| Accrued expenses and other current liabilities | 522,000 | 2 | — | — | |
| Net cash used in operating activities | −16 | −2 | −2 | −581,189 | |
| Purchase of digital assets | −2 | — | — | — | |
| Purchase of property, plant and equipment | −8,000 | — | — | — | |
| Net cash used in investing activities | −2 | — | 186 | 33,447 | |
| Proceeds from issuance of notes | 1 | 3 | — | — | |
| Proceeds from ELOC | 10 | — | — | — | |
| Proceeds from issuance of loans payable | 11 | — | — | — | |
| Proceeds from issuance of convertible loan | — | 16,000 | 1 | — | |
| Net cash received from the reverse recapitalization | 2,000 | — | — | — | |
| Repayment of convertible notes, senior notes, promissory notes and other | −3 | −150,000 | — | — | |
| Payment of deferred offering costs | — | −961,000 | — | — | |
| Net cash provided by financing activities | 20 | 2 | −184 | — | |
| Net increase in cash | 2 | 49,000 | −188,967 | −547,742 | |
| Assumption of net liabilities of Northview | 8 | — | — | — | |
| Increase in unpaid deferred offering costs | — | 269,000 | — | — | |
| Conversion of preferred stock into common stock | 65 | — | — | — | |
| Conversion of debt to equity | 51 | — | — | — | |
| Financing of D&O insurance premium | 657,000 | — | — | — | |
| Cash paid for interest | 296,000 | — | — | — | |
| Cash paid for taxes | 1,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Profusa, Inc.'s CIK number?
Profusa, Inc.'s SEC CIK number is 0001859807 (1859807). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Profusa, Inc.'s SEC filings?
All of Profusa, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.